<DOC>
	<DOCNO>NCT02842359</DOCNO>
	<brief_summary>Primary Objective : To evaluate effect irbesartan/atorvastatin fixed-dose combination compare irbesartan atorvastatin flow mediate dilation change type 2 diabetic patient diagnose hyperlipidemia , hypertension . Secondary Objective : To evaluate efficacy blood pressure hyperlipidemic factor irbesartan/atorvastatin fixed-dose combination type 2 diabetic patient diagnose hyperlipidemia hypertension , adequately control blood glucose level group .</brief_summary>
	<brief_title>Evaluation Fixed-dose Combination Irbesartan/Atorvastatin Type 2 Diabetic Patients Diagnosed With Hyperlipidemia Hypertension</brief_title>
	<detailed_description>The total study duration per patient maximum 7 week .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Inclusion criterion : Patients age ≥19 year &lt; 75 year . Patients without medication history hyperlipidemia hypertension within 3 month follow registration , among type 2 diabetic patient diagnose hyperlipidemia stage I hypertension ( systolic blood pressure : ≥140mmHg , ≤159 mmHg diastolic blood pressure : ≥90 mmHg , ≤99mmHg ) , adequately control hemoglobin level . Patients sign write consent data utilization . Diagnosis diabetes : HemoglobinA1c ≥6.5 % ; Fasting plasma glucose level 8 hour ≥126 mg/dL ; Plasma glucose ≥200 mg/dL ( 11.1 mmol/l ) 2 hour 75g glucose load ; Symptoms ( polyuria , polydipsia , unexplained weight loss ) random plasma glucose ≥200 mg/dL ( 11.1 mmol/L ) . Exclusion criterion : Patients indicated contraindication approve labeling Rovelito . Pregnant/nursing woman . Patients difference blood pressure systolic blood pressure ≥20 mmHg diastolic blood pressure ≥10mmHg arm select screen Visit 1 . Patients administer Angiotensin II receptor blocker , angiotensin convert enzyme inhibitor , HMGCoA reductase inhibitor 2 month . Patients take antidiabetic past . Patients may take drug suggest prohibit concomitant medication study period . Patients tolerance hypersensitivity angiotensin II receptor blocker HMGCoA reductase inhibitor , ingredient drug , history multidrug allergy . Patients genetic angioedema , medical history angioedema treat angiotensin convert enzyme inhibitor angiotensin II receptor antagonist Patients suffer fibromyalgia , myopathy , rhabdomyolysis , sudden arthralgia , adverse event take statin past . Creatine phosphokinase ( CPK ) &gt; 5 time upper limit normal ( ULN ) . Patients diagnose secondary hypertension suspect secondary hypertension Investigator ( coarctation aorta , primary aldosteronism , renal artery stenosis , renal hypertension , pheochromocytoma , Cushing syndrome , etc. ) . Patients poorly control hypothyroidism despite treatment Type 1 diabetic patient poorly control type 2 diabetic patient ( HemoglobinA1c ≥7.5 % ) Patients arrhythmia require separate treatment . Patients follow past history : Severe cerebrovascular disease ( cerebral infarction , cerebral hemorrhage , etc . ) , hypertensive encephalopathy , transient ischemic attack ( TIA ) , occur recent 6 month . Severe heart disease ( NYHA class IIIIV heart failure ) , clinically significant valvular disease heart , myocardial infarction unstable angina recent 6 month . Angioplasty coronary artery bypass graft ( CABG ) surgery . If patient clinically significant renal hepatic disease , significant hematologic test finding screen ( serum creatinine ≥ 2mg/dL , AST ALT [ aspartate transaminase alanine transaminase ] ≥3 time ULN ) . Patients suspect pancreatitis active gall bladder disease Investigator . Surgical internal disease likely significantly change absorption , distribution , metabolism , elimination drug , fall one following ( limited ) : Major gastrointestinal surgical history gastrectomy , gastroenterostomy bowel resection , gastric bypass , gastrointestinal stapling , gastrointestinal banding , medical history active inflammatory bowel syndrome present past 12 month , current active gastritis , ulcer , gastrointestinal/rectal hemorrhage , urinary tract obstruction deem clinically significant Investigator . Patients volume depletion , clinically judge Investigator , use vital sign , skin turgor pressure , mucous membrane wettability , laboratory value . All chronic inflammatory patient require chronic inflammatory treatment . Patients past history autoimmune disease , chronic rheumatoid arthritis , systemic lupus erythematosus , etc . Patients past clinical history alcohol drug abuse . Patients history malignant tumor include leukemia lymphoma past 5 year . Patients administer another investigational product within 30 day prior participation clinical study ( time sign informed consent form ) . Patients may measure flow mediate dilatation Investigator 's judgment congenital secondary reason bilateral brachial artery . Patients deem ineligible subject Investigator 's judgment reason . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>